NEW YORK (GenomeWeb) — The University of Texas MD Anderson Cancer Center and Foundation Medicine will work together to conduct a randomized controlled trial to compare standard treatment with targeted therapies selected based on the molecular alterations in a patient's tumor.

Led by MD Anderson's Apostolia Tsimberidou, the study, IMPACT2, will evaluate whether genomically guided cancer care results in longer progression-free survival in patients with advanced disease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.